Analyst consensus rating
Unicycive Therapeutics Analyst Rating: none
Direct answer
Unicycive Therapeutics's consensus rating is none.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $29.60.
Forecast evidence checked September 18, 2026.
Get free Unicycive Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.79
- Average price target
- $29.60
- High price target
- $50.00
- Low price target
- $15.00
- Low target gap
- +213.5%
- Target upside
- +518.6%
- High target gap
- +944.9%
- Target range width
- 731.5%
- Consensus rating
- none
- Analysts
- 10
- Evidence date
- September 18, 2026
- Valid through
- September 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Unicycive Therapeutics?
Unicycive Therapeutics has a verified none consensus. The same dataset has an average price target of $29.60.
How far are Unicycive Therapeutics's low and high targets from the recorded price?
The low target implies +213.5%, while the high target implies +944.9%.
How many analysts are included in Unicycive Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Unicycive Therapeutics's target upside or downside calculated?
The average target of $29.60 is divided by the recorded price of $4.79, then one is subtracted to produce +518.6%. This does not guarantee a future return.
When was Unicycive Therapeutics's analyst forecast verified?
The data was verified on 2026-09-18. The dataset is valid through 2026-09-25.